AU3596199A - Treatment of celiac disease - Google Patents

Treatment of celiac disease

Info

Publication number
AU3596199A
AU3596199A AU35961/99A AU3596199A AU3596199A AU 3596199 A AU3596199 A AU 3596199A AU 35961/99 A AU35961/99 A AU 35961/99A AU 3596199 A AU3596199 A AU 3596199A AU 3596199 A AU3596199 A AU 3596199A
Authority
AU
Australia
Prior art keywords
treatment
celiac disease
celiac
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU35961/99A
Inventor
Ove Noren
Hans Sjostrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobenhavns Universitet
Original Assignee
Kobenhavns Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobenhavns Universitet filed Critical Kobenhavns Universitet
Publication of AU3596199A publication Critical patent/AU3596199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU35961/99A 1998-05-06 1999-05-06 Treatment of celiac disease Abandoned AU3596199A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK62198 1998-05-06
DK621/98 1998-05-06
US9154598P 1998-07-01 1998-07-01
US60091545 1998-07-01
PCT/DK1999/000255 WO1999056698A2 (en) 1998-05-06 1999-05-06 Treatment of celiac disease

Publications (1)

Publication Number Publication Date
AU3596199A true AU3596199A (en) 1999-11-23

Family

ID=26064330

Family Applications (1)

Application Number Title Priority Date Filing Date
AU35961/99A Abandoned AU3596199A (en) 1998-05-06 1999-05-06 Treatment of celiac disease

Country Status (3)

Country Link
EP (1) EP1075267A2 (en)
AU (1) AU3596199A (en)
WO (1) WO1999056698A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
PT1191025E (en) 1999-06-30 2005-09-30 Takeda Pharmaceutical LANSOPRAZOL CRYSTALS
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7303871B2 (en) 2002-02-14 2007-12-04 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
EP2596792A1 (en) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
ES2383595T3 (en) * 2002-11-20 2012-06-22 The Board Of Trustees Of The Leland Stanford Junior University Celiac disease diagnostic procedure
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
ITMI20062080A1 (en) * 2006-10-30 2008-04-30 Consiglio Nazionale Ricerche TREATMENT OF CEREAL FLOURS FOR FOOD CONSUMPTION BY CELIAC PATIENTS
CA2680590C (en) 2007-03-16 2017-10-17 Jonathan David Gass Combination enzyme therapy for digestion of dietary gluten
PT2262790T (en) 2008-03-10 2017-07-18 Takeda Pharmaceuticals Co Crystal of benzimidazole compound
CN107831318B (en) * 2011-01-20 2021-06-18 西瑞斯实验室有限公司 Method and device for detecting gluten sensitivity and differentiating it from celiac disease
WO2012108827A1 (en) * 2011-02-08 2012-08-16 Phadia Ab Wheat antigens and peptides for diagnosis of wheat induced hypersensitivity
ITSR20130002A1 (en) * 2013-10-08 2015-04-08 Danilo Ciciulla NEW INDUSTRIAL PROCESS OF PROCESSING FOR THE PRODUCTION OF FARINACEOUS FOODS, INTENDED FOR SUBJECTS WITH CELIAC DISEASE CLINICALLY MANIFESTED, BASED ON COMMON FLOURS.
WO2017089961A1 (en) * 2015-11-24 2017-06-01 Universidade De Trás-Os-Montes E Alto Douro Process for preparing cereal flours enriched with l-theanine and corresponding products
CN105434459A (en) * 2015-12-25 2016-03-30 南阳医学高等专科学校 Formula of western medicine for treating ulcer and preparation process for western medicine
IT201800010305A1 (en) 2018-11-13 2020-05-13 Danilo Ciciulla PROCEDURE FOR THE PREPARATION OF WHEAT-BASED FOODS INTENDED FOR CELIACS OR SUBJECTS WITH GLUTEN SENSITIVITY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
DD262999A1 (en) * 1987-07-27 1988-12-21 Adw Ddr METHOD FOR PRODUCING A DIETETIC FOR ZOELIAKIE AND SPRUCE BARRIER
SU1581315A1 (en) * 1987-12-07 1990-07-30 Пятигорский научно-исследовательский институт курортологии и физиотерапии Method of treating celiac disease of children
EP0444829A3 (en) * 1990-02-27 1992-06-03 Fisons Plc Immunosuppressive compounds
IT1247489B (en) * 1991-04-17 1994-12-17 Prodotti Chimici Alimentari METHYLTAUROUROXODESOXICOLIC ACID AND ITS THERAPEUTICALLY ACTIVE DERIVATIVES PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
DE19630557C2 (en) * 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Method for the detection of antibodies from body fluids by an immune reaction with tissue transglutaminase (tTG) as well as the use of tTG in diagnosis and therapy

Also Published As

Publication number Publication date
WO1999056698A2 (en) 1999-11-11
WO1999056698A3 (en) 1999-12-29
EP1075267A2 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
AU1450900A (en) Methods of treatment of type 2 diabetes
AU3891299A (en) Combination therapy for treatment of depression
AU3596199A (en) Treatment of celiac disease
AU1772399A (en) Well treatment
AU3784999A (en) Methods for treatment of pain
AU1697197A (en) Immunoconjugate for the treatment of aids
AUPO871397A0 (en) Improved treatment of hides
AU8451298A (en) Treatment of fabrics
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU6883398A (en) Methods of treating bone loss
AU3760900A (en) Treatment of menstrual function
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
EP1107778A4 (en) Treatment of disease states
AU1405001A (en) Treatment of diseases
AU2619199A (en) Treatment of waxes
AU1931895A (en) Treatment of graft-versus-host disease
AUPP229598A0 (en) Treatment of sunburn
AU7545998A (en) Treatment of osteoporosis
AU6037499A (en) Methods of treating viral disease
AU5524399A (en) Inorgasmia treatment
AU6112299A (en) Treatment of effluents
PL346528A1 (en) Treatment of depression
AU5753599A (en) Treatment of fibres
AUPO598197A0 (en) Treatment of hides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase